Imaging of Pancreatic Adenocarcinoma: Update on Staging/Resectability

Radiologic Clinics of North America

Volumn 50, Issue 3, 2012, Pages 407-428

  Tamm, Eric P ^a   Balachandran, Aparna ^a   Bhosale, Priya R ^a   Katz, Matthew H ^a   Fleming, Jason B ^a   Lee, Jeffrey H ^a   Varadhachary, Gauri R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Imaging; Pancreatic adenocarcinoma; Pancreatic cancer; Resectability; Staging; Treatment

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE; FLUOROURACIL; GADOXETIC ACID;

ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; HEPATIC ARTERY; HEPATIC ARTERY SEGMENTAL RESECTION; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; LIVER METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; VEIN ANASTOMOSIS; VEIN RECONSTRUCTION;

ADENOCARCINOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860573042     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2012.03.008     Document Type: Review

References (72)

1. Wolff R.A., Abbruzzese J.L., Evans D.B. Neoplasms of the exocrine pancreas. Cancer medicine 2003, 1585-1614. American Cancer Society and BC Decker, Hamilton (Ontario). 6th edition. R.C. Bast, D.W. Kufe, R.E. Pollock (Eds.).
2. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189(1):1-7.
3. Katz M.H., Wang H., Fleming J.B., et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009, 16(4):836-847.
4. Tseng J.F., Raut C.P., Lee J.E., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004, 8(8):935-949. [discussion: 949-50].
5. Lall C.G., Howard T.J., Skandarajah A., et al. New concepts in staging and treatment of locally advanced pancreatic head cancer. AJR Am J Roentgenol 2007, 189(5):1044-1050.
6. Christians K.K., Lal A., Pappas S., et al. Portal vein resection. Surg Clin North Am 2010, 90(2):309-322.
7. Evans D.B., Farnell M.B., Lillemoe K.D., et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009, 16(7):1736-1744.
8. Clark L.R., Jaffe M.H., Choyke P.L., et al. Pancreatic imaging. Radiol Clin North Am 1985, 23(3):489-501.
9. Balachandran A., Darden D.L., Tamm E.P., et al. Arterial variants in pancreatic adenocarcinoma. Abdom Imaging 2008, 33(2):214-221.
10. Okahara M., Mori H., Kiyosue H., et al. Arterial supply to the pancreas; variations and cross-sectional anatomy. Abdom Imaging 2010, 35(2):134-142.
11. Katz M.H., Fleming J.B., Lee J.E., et al. Current status of adjuvant therapy for pancreatic cancer. Oncologist 2010, 15(11):1205-1213.
12. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230(6):776-782. [discussion: 782-4].
13. Smeenk H.G., van Eijck C.H., Hop W.C., et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007, 246(5):734-740.
14. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358(9293):1576-1585.
15. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1200-1210.
16. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299(9):1019-1026.
17. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120(8):899-903.
18. Aloia T.A., Lee J.E., Vauthey J.N., et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?. J Am Coll Surg 2007, 204(3):347-355.
19. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006, 13(8):1035-1046.
20. Sasson A.R., Wetherington R.W., Hoffman J.P., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer 2003, 34(2-3):121-128.
21. White R.R., Xie H.B., Gottfried M.R., et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005, 12(3):214-221.
22. Pingpank J.F., Hoffman J.P., Ross E.A., et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001, 5(2):121-130.
23. Heinrich S., Schafer M., Weber A., et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008, 248(6):1014-1022.
24. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3496-3502.
25. Varadhachary G.R., Wolff R.A., Crane C.H., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3487-3495.
26. Heinrich S., Pestalozzi B.C., Schafer M., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(15):2526-2531.
27. Exocrine and endocrine pancreas. AJCC cancer staging manual 2010, 241-250. Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
28. Fuhrman G.M., Leach S.D., Staley C.A., et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996, 223(2):154-162.
29. Tempero M.A., Arnoletti J.P., Behrman S., et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010, 8(9):972-1017.
30. National Comprehensive Cancer Network I. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. [pdf file]. 2011. 1.2012. Available at: . Accessed November 7, 2011. http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.
31. Katz M.H., Pisters P.W., Lee J.E., et al. Borderline resectable pancreatic cancer: what have we learned and where do we go from here?. Ann Surg Oncol 2011, 18(3):608-610.
32. Abrams R.A., Lowy A.M., O'Reilly E.M., et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009, 16(7):1751-1756.
33. Kim T., Murakami T., Takahashi S., et al. Pancreatic CT imaging: effects of different injection rates and doses of contrast material. Radiology 1999, 212(1):219-225.
34. Schueller G., Schima W., Schueller-Weidekamm C., et al. Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast. Radiology 2006, 241(2):441-448.
35. Tublin M.E., Tessler F.N., Cheng S.L., et al. Effect of injection rate of contrast medium on pancreatic and hepatic helical CT. Radiology 1999, 210(1):97-101.
36. Fletcher J.G., Wiersema M.J., Farrell M.A., et al. Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology 2003, 229(1):81-90.
37. Fayad L.M., Mitchell D.G. Magnetic resonance imaging of pancreatic adenocarcinoma. Int J Gastrointest Cancer 2001, 30(1-2):19-25.
38. Pamuklar E., Semelka R.C. MR imaging of the pancreas. Magn Reson Imaging Clin North Am 2005, 13(2):313-330.
39. Kim J.H., Park S.H., Yu E.S., et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010, 257(1):87-96.
40. Tamm E.P., Loyer E.M., Faria S.C., et al. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging 2007, 32(5):660-667.
41. Wiersema M.J., Vilmann P., Giovannini M., et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997, 112(4):1087-1095.
42. Giovannini M. The place of endoscopic ultrasound in bilio-pancreatic pathology. Gastroenterol Clin Biol 2010, 34(8-9):436-445.
43. Strobel K., Heinrich S., Bhure U., et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008, 49(9):1408-1413.
44. Delbeke D., Martin W.H. PET and PET/CT for pancreatic malignancies. Surg Oncol Clin North Am 2010, 19(2):235-254.
45. Lu D.S., Reber H.A., Krasny R.M., et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997, 168(6):1439-1443.
46. Lee J.K., Kim A.Y., Kim P.N., et al. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma. Eur J Radiol 2010, 73(2):310-316.
47. Kaneko O.F., Lee D.M., Wong J., et al. Performance of multidetector computed tomographic angiography in determining surgical resectability of pancreatic head adenocarcinoma. J Comput Assist Tomogr 2010, 34(5):732-738.
48. Zamboni G.A., Kruskal J.B., Vollmer C.M., et al. Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology 2007, 245(3):770-778.
49. Tamm E.P., Loyer E.M., Faria S., et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 2006, 31(5):568-574.
50. Valls C., Andia E., Sanchez A., et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002, 178(4):821-826.
51. Arslan A., Buanes T., Geitung J.T. Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur J Radiol 2001, 38(2):151-159.
52. Aslanian H., Salem R., Lee J., et al. EUS diagnosis of vascular invasion in pancreatic cancer: surgical and histologic correlates. Am J Gastroenterol 2005, 100(6):1381-1385.
53. Soriano A., Castells A., Ayuso C., et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004, 99(3):492-501.
54. Dewitt J., Devereaux B.M., Lehman G.A., et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol 2006, 4(6):717-725. [quiz: 664].
55. Pakzad F., Groves A.M., Ell P.J. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006, 36(3):248-256.
56. Bares R., Dohmen B.M., Cremerius U., et al. Radiologe 1996, 36(5):435-440. [in German].
57. Bares R., Klever P., Hauptmann S., et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994, 192(1):79-86.
58. Kala Z., Valek V., Hlavsa J., et al. The role of CT and endoscopic ultrasound in pre-operative staging of pancreatic cancer. Eur J Radiol 2007, 62(2):166-169.
59. Mitsuhashi T., Ghafari S., Chang C.Y., et al. Endoscopic ultrasound-guided fine needle aspiration of the pancreas: cytomorphological evaluation with emphasis on adequacy assessment, diagnostic criteria and contamination from the gastrointestinal tract. Cytopathology 2006, 17(1):34-41.
60. Giovannini M., Thomas B., Erwan B., et al. Endoscopic ultrasound elastography for evaluation of lymph nodes and pancreatic masses: a multicenter study. World J Gastroenterol 2009, 15(13):1587-1593.
61. Richter G.M., Simon C., Hoffmann V., et al. Radiologe 1996, 36(5):397-405. [in German].
62. Trede M., Rumstadt B., Wendl K., et al. Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors. Ann Surg 1997, 226(4):393-405. [discussion: 405-7].
63. Calculli L., Casadei R., Diacono D., et al. Radiol Med 1998, 95(4):344-348. [in Italian].
64. Ikuta Y., Takamori H., Ikeda O., et al. Detection of liver metastases secondary to pancreatic cancer: utility of combined helical computed tomography during arterial portography with biphasic computed tomography-assisted hepatic arteriography. J Gastroenterol 2010, 45(12):1241-1246.
65. Motosugi U., Ichikawa T., Morisaka H., et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011, 260(2):446-453.
66. Sahani D.V., Kalva S.P., Fischman A.J., et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005, 185(1):239-246.
67. Frohlich A., Diederichs C.G., Staib L., et al. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999, 40(2):250-255.
68. Diederichs C.G. Pancreatic cancer. PET in oncology 1999, 128-134. Springer-Verlag, Berlin. J. Ruhlmann, P. Oehr, H.J. Biersack (Eds.).
69. Pisters P.W., Lee J.E., Vauthey J.N., et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001, 88(3):325-337.
70. Izuishi K., Yamamoto Y., Sano T., et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010, 14(7):1151-1158.
71. Evans D.B., Crane C.H., Charnsangavej C., et al. The added value of multidisciplinary care for patients with pancreatic cancer. Ann Surg Oncol 2008, 15(8):2078-2080.
72. Gottlieb R, et al. CT onco primary pancreas mass template. 2011. Available at: . Accessed November 14, 2011. http://www.radreport.org/txt/0000018.